1. 17P Using ex vivo organ culture technology to evaluate a T cell bispecific (TCB) CEACAM5 therapy. (December 2022) Authors: Zundelevich, A.; Ibrahim, B.; Turovsky, L.; Aharon, S.; Bar, V.; Salpeter, S.; Neev, G.; Straussman, R.; Silva, I.; Li, S.; Herter, S.; Bacac, M.; Sadok, S.; Gjorevski, N. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗